# A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

> **NCT05308654** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 34 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** ABBV-453
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT05308654
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-17
- **Primary completion:** 2024-02-07
- **Final completion:** 2025-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05308654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05308654, "A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05308654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*